A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib: Trial in Progress

Abstract | Dec 7, 2024

Author

Issa GC, et al.

Congress

American Society of Hematology Annual Meeting 2024

San Diego, California | Dec 7 – 10, 2024